$0.345
-0.022 (-6.36%)收盤時
- High
- 0.350
- Open
- 0.334
- VWAP
- 0.34
- Vol
- 466.28K
- Mkt Cap
- —
- Low
- 0.328
- Amount
- 158.97K
- EV/EBITDA, TTM
- 0.00
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
AI analysis of ENvue Medical Inc (FEED)
sellENvue Medical, Inc. is not a good buy right now due to its significantly low price and poor financial performance. The current price is $0.34, and the stock has experienced a year-to-date change of -85.94%. Additionally, the RSI is at 23.926, indicating that the stock is oversold, but this could signal further downside risk rather than a buying opportunity. The company also reported a staggering net income loss of -22,621,000 USD in the most recent quarter, which raises concerns about its financial health.
估值指標
事件時間軸
資訊
8.508-28NewsfilterENvue Medical Announces Reverse Stock Split Effective September 1, 2026
8.508-28NASDAQ.COMENvue Medical Announces 1-for-12 Reverse Stock Split
8.508-12NewsfilterENvue Medical Secures $50 Million Equity Facility
7.507-23NewsfilterENvue Medical Expands Navigation Platform in Texas
8.507-09NewsfilterENvue Medical Unveils Next-Gen Intelligent Bedside Procedure Tool
FEED FAQ — answered by Alphio AI
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.
ENvue Medical, Inc. is not a good buy right now due to its significantly low price and poor financial performance. The current price is $0.34, and the stock has experienced a year-to-date change of -85.94%. Additionally, the RSI is at 23.926, indicating that the stock is oversold, but this could signal further downside risk rather than a buying opportunity. The company also reported a staggering net income loss of -22,621,000 USD in the most recent quarter, which raises concerns about its financial health.
本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。